Some cancer medicines can lead to a new, different cancer during treatment or years later. Each medicine's label says what to watch for: regular blood counts on olaparib and niraparib, skin checks on vemurafenib, encorafenib and ripretinib, prompt tests for unexpected vaginal bleeding on tamoxifen, and lifelong follow-up after CAR T cells. Your own team's plan comes first.
This page sets out what the US label and the EU summary of product characteristics (SmPC) ask for, product by product, with the few guideline statements that could be read. The local protocol and the label in force where the patient is treated come first.
PARP inhibitors. The US olaparib label reports myelodysplastic syndrome or acute myeloid leukaemia (MDS/AML) in approximately 1.2% (26/2219) of patients, and 8% against 4% with placebo in SOLO2. It asks for a blood count at baseline and monthly; for prolonged toxicity, interruption and weekly counts; referral to a haematologist, with bone marrow analysis and cytogenetics, if counts have not recovered to grade 1 or less after 4 weeks; and discontinuation if MDS/AML is confirmed. The EU SmPC recommends monthly counts for the first 12 months and periodically afterwards. For niraparib both labels ask for weekly counts in the first month; monthly counts then run for the next 11 months in the US label and the next 10 in the EU SmPC. The US label reports MDS/AML in 3.3% against 2.4% with placebo in PRIMA (HRD-positive patients) and 7% against 3% in the germline BRCA cohort of NOVA. ASCO's 2020 guideline, since replaced, recommended starting an evaluation for treatment-related MDS/AML when a cytopenia persists despite a drug hold; the living guideline that replaced it in October 2026 was read as an abstract only, which says clinicians should monitor for serious adverse events including MDS and AML.
Lutetium-177 dotatate. The US label reports MDS in 2.3% in NETTER-1, and in ERASMUS MDS in 2.0% and acute leukaemia in 0.5%, at a median of 29 and 55 months. The US label says to monitor blood cell counts and sets no schedule after treatment ends. The EU SmPC recommends blood counts, kidney and liver tests every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter, to detect possible delayed adverse reactions. The NANETS/SNMMI procedure standard (2019) asks for blood tests at roughly 1, 3, 6 and 12 months after treatment, then at least yearly, and says a haematology consult should be considered for persistent cytopenias.
BRAF inhibitors and ripretinib. On vemurafenib, cutaneous squamous cell carcinoma or keratoacanthoma occurred in 24% (US label). Skin is examined before treatment and every 2 months in the US labels for vemurafenib, encorafenib and dabrafenib; the EU SmPCs ask for monthly examination on vemurafenib and dabrafenib and every 2 months on encorafenib. Suspicious lesions are excised and sent for dermatopathology and the drug continues at the same dose. The EU SmPCs add a head and neck examination and CT scans to look for cancers outside the skin (at set intervals for vemurafenib, as clinically appropriate for dabrafenib and encorafenib); the US labels ask for monitoring of signs and symptoms. Ripretinib (cutaneous squamous cell carcinoma in 4.7% of 85 patients in INVICTUS, US label): skin examination at the start and routinely, in both labels.
Lenalidomide. After high-dose melphalan and autologous transplant, haematological second cancers occurred in 7.5% on maintenance against 3.3% on placebo (US label). The US label says to monitor for second primary malignancies and to weigh the benefit of lenalidomide against that risk; the EU SmPC asks for standard cancer screening before and during treatment.
Tamoxifen. Abnormal vaginal bleeding during or after tamoxifen is evaluated promptly (US label, UK SmPC); ACOG says any abnormal vaginal bleeding in a woman taking tamoxifen should be investigated. The US label also asks for an annual gynaecological examination; the UK SmPC read does not. ACOG does not recommend routine endometrial surveillance unless the woman is at high risk of endometrial cancer.
CAR T cells. The US labels of all six BCMA- and CD19-directed products (ciltacabtagene autoleucel, idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel and axicabtagene ciloleucel), the EU SmPC for ciltacabtagene autoleucel, the FDA and the EMA's safety committee all ask for lifelong monitoring for secondary malignancies. The labels and the FDA also ask for the manufacturer to be contacted if one occurs, to get instructions on samples for testing.
Why: The US label reports MDS/AML in approximately 1.2% of patients given olaparib in its trials, fatal in 14 of the 26 cases, and asks for monthly counts to look for clinically significant changes. The EU SmPC recommends monthly counts for the first 12 months and periodically after that. For niraparib both labels ask for weekly counts in the first month, then monthly for the next 11 months (US) or the next 10 months (EU), then periodically.
“Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment.”
Why: This is the US label's rule for prolonged haematological toxicity. The EU SmPC says to interrupt olaparib for severe haematological toxicity or blood transfusion dependence, and that if blood parameters remain clinically abnormal after 4 weeks of interruption, bone marrow analysis and/or blood cytogenetic analysis are recommended, and that a patient with suspected MDS/AML should be referred to a haematologist. For niraparib the US label says to discontinue it and refer to a haematologist if haematological toxicities do not resolve within 28 days of interruption.
“If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.”
Why: The US label and the EU SmPC for niraparib both say this, and the EU olaparib SmPC asks for the same referral when MDS/AML is suspected. ASCO's 2020 guideline on PARP inhibitors in ovarian cancer, since replaced, said evaluation for treatment-related MDS/AML should be started when a cytopenia persists despite a drug hold. The living guideline that replaced it in October 2026 was read as an abstract only; the abstract says clinicians should monitor for serious adverse events including MDS and AML.
“For suspected MDS/AML or prolonged hematological toxicities, refer the patient to a hematologist for further evaluation.”
Why: Both US labels and both EU SmPCs say so. The EU SmPCs add that the patient should be treated appropriately. The labels give no reason beyond the diagnosis itself.
“Discontinue ZEJULA if MDS/AML is confirmed.”
Why: The NANETS/SNMMI standard calls secondary myelodysplastic syndrome and acute leukaemia known toxicities of this treatment. The US label gives a median onset of 29 months for MDS and 55 months for acute leukaemia and sets no blood test schedule after treatment ends. The EU SmPC sets a different one: blood counts, kidney and liver tests every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter, to detect possible delayed adverse reactions.
“Blood tests including complete blood count with differential, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, albumin, and serum creatinine/GFR should be monitored at roughly 1 mo, 3 mo, 6 mo, and 12 mo after treatment.”
Why: The standard recommends increased monitoring with blood tests until recovery for patients with persistent cytopenias. It words the haematology consult as something that should be considered.
“In addition, hematology consult should be considered for patients with persistent cytopenias.”
Why: The US vemurafenib label reports cutaneous squamous cell carcinoma or keratoacanthoma in 24% of patients, with a median of 7 to 8 weeks to the first one. The EU SmPC for encorafenib, like the US label, says every 2 months. All of them carry the checks on for up to 6 months after the drug is stopped; the US vemurafenib label words that as something to consider.
“Perform dermatologic evaluations prior to initiation of therapy and every 2 months while on therapy.”
Why: The labels for vemurafenib and encorafenib in both regions say to manage suspicious lesions by excision and dermatopathological evaluation and to carry on without a dose change. The dabrafenib labels also leave the dose unchanged. None gives a further reason.
“Manage suspicious skin lesions with excision and dermatopathologic evaluation. Dose modification is not recommended for new primary cutaneous malignancies.”
Why: The SmPC says squamous cell carcinomas outside the skin have been reported in trials of vemurafenib. The US label asks only that patients be monitored closely for signs or symptoms of them. The EU SmPCs for dabrafenib and encorafenib list the same kinds of check, worded differently (see variants).
“Patients should undergo a head and neck examination, consisting of at least a visual inspection of oral mucosa and lymph node palpation prior to initiation of treatment and every 3 months during treatment.”
Why: The US label says that, from its mechanism of action, encorafenib may promote malignancies associated with activation of RAS. The US dabrafenib label says to permanently discontinue dabrafenib for the same finding, while the EU dabrafenib SmPC says benefits and risks should be considered before continuing. Neither vemurafenib label gives a stopping rule.
“Discontinue BRAFTOVI for RAS mutation-positive noncutaneous malignancies”
Why: The US label reports cutaneous squamous cell carcinoma in 4.7% of the 85 patients given ripretinib in INVICTUS, and melanoma in 2.4%. The EU SmPC has the same instructions. Neither sets an interval.
“Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment.”
Why: This is the EU SmPC's wording, which also says the risk of a haematological second cancer must be taken into account before lenalidomide is started with melphalan or straight after high-dose melphalan and transplant. The US label says to monitor patients for the development of second primary malignancies and to take both the benefit and that risk into account when considering treatment. Neither names a test or an interval.
“Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of SPM and institute treatment as indicated.”
Why: The US label says an increased incidence of uterine malignancies has been reported with tamoxifen, and its boxed warning says some were fatal. The UK SmPC read says the same of any abnormal gynaecological symptom, especially vaginal bleeding. The US label also says these women should have annual gynaecological examinations; the UK SmPC sets no routine examination.
“Any patient receiving or who has previously received tamoxifen who reports abnormal vaginal bleeding should be promptly evaluated.”
Why: ACOG says routine surveillance has not proved effective in increasing the early detection of endometrial cancer in women using tamoxifen. The US label says that in the NSABP P-1 trial endometrial sampling did not alter the endometrial cancer detection rate. ACOG adds that such surveillance may lead to more invasive and costly diagnostic procedures. Its text does not define high risk of endometrial cancer.
“Unless the patient has been identified to be at high risk of endometrial cancer, routine endometrial surveillance has not proved to be effective in increasing the early detection of endometrial cancer in women using tamoxifen and is not recommended.”
American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice 2014
Why: The US label for ciltacabtagene autoleucel says mature T-cell malignancies, including CAR-positive tumours, may present as soon as weeks after infusion and may be fatal; its EU SmPC says they have been reported within weeks and up to several years. The US labels of the other five BCMA- and CD19-directed products (idecabtagene vicleucel, lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel and axicabtagene ciloleucel) each carry a boxed warning on T-cell malignancies and the same instruction, and the FDA and the EMA's safety committee ask for lifelong monitoring after every product they name.
“Monitor life-long for secondary malignancies.”
Why: The FDA says the samples are tested for the presence of the CAR transgene. The EMA's safety committee reported that the CAR construct was found in 7 of the cases where tissue was tested, which it says suggests the CAR T-cell medicine was involved in the disease developing.
“In the event that a new malignancy occurs following treatment with these products, contact the manufacturer to report the event and obtain instructions on collection of patient samples for testing for the presence of the CAR transgene.”
US Food and Drug Administration, Center for Biologics Evaluation and Research 2024
Why: The US olaparib label says these symptoms may be a sign of haematological toxicity or of MDS or AML. The US labels for vemurafenib, encorafenib and ripretinib ask that patients contact their healthcare provider immediately about skin changes, and the US tamoxifen label that women promptly report abnormal gynaecological symptoms.
“Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
For most of these medicines the product label is the only source that sets a monitoring rule, and the US and EU texts do not always agree. Where a guideline could be read it is shown beside the label. PARP inhibitors: monthly blood counts on olaparib (US label: throughout treatment; EU SmPC: for the first 12 months, then periodically); on niraparib weekly for a month, then monthly for 11 months (US) or 10 months (EU); referral to a haematologist when counts do not recover; discontinuation if MDS/AML is confirmed; the ASCO guideline of 2020 (informal consensus, evidence quality insufficient, strength moderate) asked for evaluation when a cytopenia persists despite a drug hold, and has since been replaced by a living guideline whose full text was not read. Lutetium-177 dotatate: the US label sets no blood test schedule after treatment; the EU SmPC recommends tests every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter; the NANETS/SNMMI standard (ungraded consensus) gives roughly 1, 3, 6 and 12 months and then at least yearly. BRAF inhibitors: skin examination before treatment, every 2 months (US labels; EU SmPC for encorafenib) or monthly (EU SmPCs for vemurafenib and dabrafenib), and for up to 6 months after stopping, with excision and no dose change; the EU SmPCs add named examinations and scans for cancers outside the skin, at set intervals for vemurafenib and as clinically appropriate for dabrafenib and encorafenib. Lenalidomide: monitoring (US) or standard cancer screening before and during treatment (EU), with no test or interval named; the IMWG consensus, read as an abstract, says the risk should be discussed carefully with the patient. Tamoxifen: prompt evaluation of abnormal bleeding everywhere; an annual gynaecological examination in the US label only; no routine endometrial surveillance unless high risk (ACOG, reaffirmed 2024). CAR T cells: lifelong monitoring and contact with the manufacturer if a new cancer occurs, in the six US labels, the EU SmPC read (ciltacabtagene autoleucel), the FDA communication and the EMA statement. The reader's own team's protocol comes first.
AstraZeneca / US FDA (DailyMed) 2025 · AstraZeneca / European Medicines Agency 2025 · GlaxoSmithKline / US FDA (DailyMed) 2026 · GlaxoSmithKline / European Medicines Agency 2026 · ASCO, Journal of Clinical Oncology (Tew et al.) 2020 · ASCO, Journal of Clinical Oncology (Tew et al.) 2026 · Advanced Accelerator Applications (Novartis) / US FDA (DailyMed) 2026 · Novartis / European Medicines Agency 2026 · North American Neuroendocrine Tumor Society and Society of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine (Hope et al.) 2019 · Genentech / US FDA (DailyMed) 2026 · Roche / European Medicines Agency 2025 · Array BioPharma (Pfizer) / US FDA (DailyMed) 2026 · Pierre Fabre / European Medicines Agency 2026 · Novartis / US FDA (DailyMed) 2026 · Novartis / European Medicines Agency 2026 · Deciphera Pharmaceuticals / US FDA (DailyMed) 2025 · Deciphera Pharmaceuticals / European Medicines Agency 2026 · Celgene (Bristol Myers Squibb) / US FDA (DailyMed) 2023 · Bristol Myers Squibb / European Medicines Agency 2025 · International Myeloma Working Group, Annals of Oncology (Musto et al.) 2017 · Mylan Pharmaceuticals / US FDA (DailyMed) 2021 · Wockhardt UK / electronic medicines compendium 2026 · American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice 2014 · Janssen Biotech / US FDA (DailyMed) 2025 · Janssen-Cilag / European Medicines Agency 2026 · Celgene (Bristol Myers Squibb) / US FDA (DailyMed) 2025 · Juno Therapeutics (Bristol Myers Squibb) / US FDA (DailyMed) 2026 · Novartis / US FDA (DailyMed) 2026 · Kite Pharma / US FDA (DailyMed) 2026 · Kite Pharma / US FDA (DailyMed) 2026 · US Food and Drug Administration, Center for Biologics Evaluation and Research 2024 · European Medicines Agency 2024
Where it differs: The US label asks for a blood count at baseline and monthly thereafter, weekly counts during an interruption for prolonged toxicity, and referral to a haematologist if counts have not recovered to grade 1 or less after 4 weeks. The EU SmPC recommends monthly counts for the first 12 months and periodically after that; if blood parameters remain clinically abnormal after 4 weeks of interruption it recommends bone marrow analysis and/or blood cytogenetic analysis, and it asks for referral to a haematologist when MDS/AML is suspected.
Evidence: Regulatory labels. The EU SmPC reports that in SOLO2, 9 of the 16 MDS/AML cases in the olaparib arm occurred after olaparib had been discontinued, during survival follow-up; neither label says how long counts should continue after the drug is stopped.
AstraZeneca / US FDA (DailyMed) 2025 · AstraZeneca / European Medicines Agency 2025
Where it differs: Both ask for weekly counts for the first month. Monthly counts then run for the next 11 months in the US label and the next 10 months in the EU SmPC, and periodically afterwards in both. The US label says to discontinue niraparib and refer to a haematologist if haematological toxicities do not resolve within 28 days of interruption; the EU SmPC says niraparib should be discontinued for severe persistent haematological toxicity that does not resolve within 28 days, and that a patient with suspected MDS/AML or prolonged haematological toxicity should be referred to a haematologist.
Evidence: Regulatory labels. The US label reports MDS/AML in 3.3% against 2.4% with placebo in HRD-positive patients in PRIMA at 6.1 years of follow-up; the EU SmPC reports 2.3% against 1.6% in PRIMA at 74 months.
GlaxoSmithKline / US FDA (DailyMed) 2026 · GlaxoSmithKline / European Medicines Agency 2026
Where it differs: US labels for vemurafenib, encorafenib and dabrafenib: before treatment and every 2 months. EU SmPCs: monthly for vemurafenib and dabrafenib, every 2 months for encorafenib. After stopping, the EU SmPCs continue monitoring for 6 months or, for vemurafenib and dabrafenib, until another anticancer treatment starts; the US labels for encorafenib and dabrafenib say for up to 6 months, and the US vemurafenib label says to consider it.
Evidence: Regulatory labels; none gives a trial comparing intervals. The US vemurafenib label reports a median of 7 to 8 weeks to the first cutaneous squamous cell carcinoma.
Genentech / US FDA (DailyMed) 2026 · Roche / European Medicines Agency 2025 · Array BioPharma (Pfizer) / US FDA (DailyMed) 2026 · Pierre Fabre / European Medicines Agency 2026 · Novartis / US FDA (DailyMed) 2026 · Novartis / European Medicines Agency 2026
Where it differs: The EU vemurafenib SmPC sets a head and neck examination before treatment and every 3 months, a chest CT before treatment and every 6 months, and anal and pelvic examinations before and at the end of treatment or when clinically indicated, with monitoring continuing for up to 6 months after stopping or until another anticancer treatment starts. The EU dabrafenib SmPC asks for a head and neck examination and a chest and abdomen CT before treatment, and during treatment monitoring as clinically appropriate, which may include the same 3 and 6 month intervals. The EU encorafenib SmPC lists the same checks and blood counts before, during and at the end of treatment as clinically appropriate. The US labels ask for monitoring of signs and symptoms and name no examination or scan.
Evidence: Regulatory labels. The EU dabrafenib SmPC bases the concern on laboratory experiments showing paradoxical activation of MAP kinase signalling in cells with RAS mutations exposed to BRAF inhibitors.
Roche / European Medicines Agency 2025 · Novartis / European Medicines Agency 2026 · Pierre Fabre / European Medicines Agency 2026 · Genentech / US FDA (DailyMed) 2026 · Array BioPharma (Pfizer) / US FDA (DailyMed) 2026 · Novartis / US FDA (DailyMed) 2026
Where it differs: The US label says women taking or having taken tamoxifen should have annual gynaecological examinations. The UK SmPC read sets no routine examination and asks for prompt investigation of abnormal gynaecological symptoms. ACOG says postmenopausal women should be closely monitored for symptoms of endometrial hyperplasia or cancer, that premenopausal women need no additional monitoring beyond routine gynaecological care, and that routine endometrial surveillance is not recommended unless the woman is at high risk of endometrial cancer.
Evidence: US label: in the NSABP P-1 trial endometrial adenocarcinoma occurred at 2.20 per 1,000 women-years on tamoxifen against 0.71 on placebo, and endometrial sampling did not alter the detection rate (0.6% with sampling, 0.5% without). UK SmPC: a meta-analysis of risk reduction trials found the increase in women over 50 at randomisation and not in women under 50. ACOG Committee Opinion 601, reaffirmed 2024: it says such surveillance may lead to more invasive and costly diagnostic procedures.
Mylan Pharmaceuticals / US FDA (DailyMed) 2021 · Mayne Pharma / US FDA (DailyMed) 2021 · Wockhardt UK / electronic medicines compendium 2026 · American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice 2014
Where it differs: The EU SmPC recommends blood counts, kidney and liver tests every 4 weeks for at least 3 months after the last infusion and every 6 months thereafter, to detect possible delayed adverse reactions. The NANETS/SNMMI standard sets blood tests at roughly 1, 3, 6 and 12 months after treatment and then a blood count and creatinine at least yearly. The US label says to monitor blood cell counts and describes secondary MDS and leukaemia without a schedule. The EU SmPC also asks for blood counts at baseline and before each dose until any toxicity has resolved, and lists factors suggested as raising the risk: age over 70, impaired kidney function, baseline cytopenias, number of prior therapies, prior chemotherapy (specifically alkylating agents) and prior radiotherapy.
Evidence: Consensus procedure standard, not graded, written in 2019; regulatory labels.
North American Neuroendocrine Tumor Society and Society of Nuclear Medicine and Molecular Imaging, Journal of Nuclear Medicine (Hope et al.) 2019 · Advanced Accelerator Applications (Novartis) / US FDA (DailyMed) 2026 · Novartis / European Medicines Agency 2026
Where it differs: The EU package leaflet for ciltacabtagene autoleucel tells patients they will be asked to enrol in a registry for at least 15 years, and to talk to their doctor about any new swelling of the glands or changes in the skin such as new rashes or lumps. The US Medication Guide says the healthcare provider should monitor the patient for cancers and names no symptom.
Evidence: Regulatory patient information. The EMA's safety committee evaluated 38 cases of secondary malignancy of T-cell origin among approximately 42,500 patients treated with CAR T-cell medicines. The FDA, when it removed the REMS for these products in June 2025, said manufacturers must still run observational safety studies of secondary malignancies that follow patients for 15 years.
Janssen-Cilag / European Medicines Agency 2026 · Janssen Biotech / US FDA (DailyMed) 2025 · European Medicines Agency 2024 · US Food and Drug Administration, Center for Biologics Evaluation and Research 2025
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Evaluate for treatment-related MDS/AML when a cytopenia persists despite holding a PARP inhibitor (2020 edition, since replaced) | Type: informal consensus, benefits outweigh harms; Evidence quality: insufficient; Strength of recommendation: moderate | ASCO, Journal of Clinical Oncology (Tew et al.) 2020 |
| Monitor for serious adverse events including MDS and AML on PARP inhibitors (2026 living guideline; grade not in abstract) “Clinicians should monitor for serious adverse events, including myelodysplastic syndrome, acute myeloid leukemia, and pulmonary complications.” | grade not given in the abstract | ASCO, Journal of Clinical Oncology (Tew et al.) 2026 |
| Olaparib, EU: monthly blood counts for the first 12 months, then periodically “Baseline testing, followed by monthly monitoring, of complete blood counts is recommended for the first 12 months of treatment and periodically after this time” | regulatory label (not graded) | AstraZeneca / European Medicines Agency 2025 |
| Niraparib, US: weekly counts for a month, monthly for the next 11 months, then periodically “Monitor complete blood counts weekly for the first month, monthly for the next 11 months of treatment, and periodically after this time.” | regulatory label (not graded) | GlaxoSmithKline / US FDA (DailyMed) 2026 |
| Niraparib, EU: weekly counts for a month, monthly for the next 10 months, then periodically “Testing complete blood counts weekly for the first month, followed by monthly monitoring for the next 10 months of treatment and periodically after this time is recommended” | regulatory label (not graded) | GlaxoSmithKline / European Medicines Agency 2026 |
| Lutetium-177 dotatate, EU: laboratory tests every 4 weeks for at least 3 months after the last infusion, then every 6 months “It is also recommended to perform these tests every 4 weeks for at least 3 months after the last infusion of Lutathera and every 6 months thereafter, in order to be able to detect possible delayed adverse reactions (see section 4.8).” | regulatory label (not graded) | Novartis / European Medicines Agency 2026 |
| Lutetium-177 dotatate, EU: blood counts at baseline and before each dose “blood counts must be monitored at baseline and prior to each dose of Lutathera during treatment and until resolution of any eventual toxicity” | regulatory label (not graded) | Novartis / European Medicines Agency 2026 |
| Vemurafenib, EU: monthly skin examination during treatment and up to six months after “The prescriber should examine the patient monthly during and up to six months after treatment for cuSCC.” | regulatory label (not graded) | Roche / European Medicines Agency 2025 |
| Dabrafenib, US: skin examination before treatment, every 2 months, and for up to 6 months after “Perform dermatologic evaluations prior to initiation of TAFINLAR, every 2 months while on therapy, and for up to 6 months following discontinuation of TAFINLAR.” | regulatory label (not graded) | Novartis / US FDA (DailyMed) 2026 |
| Dabrafenib, EU: skin examination before treatment, monthly, and for up to six months after “It is recommended that skin examination be performed prior to initiation of therapy with dabrafenib and monthly throughout treatment and for up to six months after treatment for cuSCC.” | regulatory label (not graded) | Novartis / European Medicines Agency 2026 |
| Encorafenib, EU: consider stopping for good if a RAS mutation-positive cancer outside the skin develops “It should be considered to permanently discontinue encorafenib in patients who develop RAS mutation-positive non-cutaneous malignancies.” | regulatory label (not graded) | Pierre Fabre / European Medicines Agency 2026 |
| Ripretinib, EU: skin examination at the start and routinely “Dermatological evaluations should be performed when initiating ripretinib and routinely during treatment.” | regulatory label (not graded) | Deciphera Pharmaceuticals / European Medicines Agency 2026 |
| Lenalidomide, US: monitor for second primary malignancies “Monitor patients for the development of second primary malignancies.” | regulatory label (not graded) | Celgene (Bristol Myers Squibb) / US FDA (DailyMed) 2023 |
| Myeloma: discuss the risk of a second cancer with the patient when treatments are weighed “SPM risk should be carefully discussed with the patient in the context of benefits and risks of different treatment options.” | expert panel consensus (grades not in abstract) | International Myeloma Working Group, Annals of Oncology (Musto et al.) 2017 |
| Tamoxifen, US: annual gynaecological examination “Patients receiving or who have previously received tamoxifen should have annual gynecological examinations.” | regulatory label (not graded) | Mayne Pharma / US FDA (DailyMed) 2021 |
| Tamoxifen, UK: prompt investigation of abnormal gynaecological symptoms “Any patient receiving or having previously received tamoxifen who reports abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.” | regulatory label (not graded) | Wockhardt UK / electronic medicines compendium 2026 |
| Tamoxifen: premenopausal women need no monitoring beyond routine gynaecological care “Premenopausal women treated with tamoxifen have no known increased risk of uterine cancer and require no additional monitoring beyond routine gynecologic care.” | committee opinion (not graded) | American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice 2014 |
| CAR T cells, EU label: lifelong monitoring for secondary malignancies “Patients should be monitored life-long for secondary malignancies.” | regulatory label (not graded) | Janssen-Cilag / European Medicines Agency 2026 |
| Idecabtagene vicleucel, US label: lifelong monitoring for secondary malignancies “Monitor life-long for secondary malignancies.” | regulatory label (not graded) | Celgene (Bristol Myers Squibb) / US FDA (DailyMed) 2025 |
| Lisocabtagene maraleucel, US label: lifelong monitoring for secondary malignancies “Monitor lifelong for secondary malignancies.” | regulatory label (not graded) | Juno Therapeutics (Bristol Myers Squibb) / US FDA (DailyMed) 2026 |
| Tisagenlecleucel, US label: lifelong monitoring for secondary malignancies “Monitor life-long for secondary malignancies.” | regulatory label (not graded) | Novartis / US FDA (DailyMed) 2026 |
| Brexucabtagene autoleucel, US label: lifelong monitoring for secondary malignancies “Monitor life-long for secondary malignancies.” | regulatory label (not graded) | Kite Pharma / US FDA (DailyMed) 2026 |
| Axicabtagene ciloleucel, US label: lifelong monitoring for secondary malignancies “Monitor life-long for secondary malignancies.” | regulatory label (not graded) | Kite Pharma / US FDA (DailyMed) 2026 |
| CAR T cells, EMA safety committee: lifelong monitoring for new malignancies “Patients treated with these medicines should be monitored life-long for new malignancies.” | regulatory statement (not graded) | European Medicines Agency 2024 |
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Brexucabtagene autoleucel, Lisocabtagene maraleucel, Axicabtagene ciloleucel, Tisagenlecleucel.
Shares Idecabtagene vicleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel, Ciltacabtagene autoleucel.
Shares Brexucabtagene autoleucel, Lisocabtagene maraleucel, Axicabtagene ciloleucel, Tisagenlecleucel.